91高清自产国产拍,无码免费A级毛片大全,日本欧美国产中文字幕,99re热视频这里只有精品视频首页

400-620-6333

提交您使用阿拉丁产品的研究文章，就得100元奖励！立即访问我们的提交页面.

语言

切换导航

我的购物车

搜索

语言

Tocilizumab (anti-IL-6R)

规格或纯度: Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

种属反应性: Cynomolgus,Human
亚型: Human IgG1

有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

货号 (SKU)	包装规格	是否现货	价格	数量
T412004-1mg	1mg	期货
T412004-5mg	5mg	期货
T412004-10mg	10mg	期货

查看相关系列

Interleukin-6 receptor Antibody

Skip to the end of the images gallery

main product photo

Skip to the beginning of the images gallery

基本信息

产品名称	Tocilizumab (anti-IL-6R)
规格或纯度	Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
特异性	IL-6Ra/CD126
应用	ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
反应种属	Cynomolgus,Human
偶联标记	Unconjugated

产品属性

抗体类型	Primary antibody
Format	Whole IgG
亚型	Human IgG1
轻链亚型	Kappa
SDS-PAGE	26.6 kDa (Light Chain) & 51.4 kDa (Heavy Chain), under reducing conditions; 174.3 kDa, under non-reducing conditions.
纯化方法	Protein A purified
来源	CHO supernatant
物理外观	Liquid
储存缓冲液	Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂	No
浓度	Lot by Lot
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	Store at -80℃ for 18 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS编号和信息	375823-41-9

数据库链接

IMGT/mAb-DB	96
PubChem SID	178103463
Wikipedia	Tocilizumab
PEP	tocilizumab
Immunopaedia Search	tocilizumab
Reactome Reaction	R-HSA-9681294
Reactome Drug	R-ALL-9681301

靶标

Target ID	2310
名称	Interleukin-6 receptor
缩写名	SHP2
家族	IL-6 receptor family

关联配体

Ligand ID	6881
名称	tocilizumab
别名	Actemra®
类别	Antibody
学名	4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide
生物活性评价	Unfortunately, we have been unable to find publicly available data providing a binding affinity for this antibody at its molecular target.
评价	Tocilizumab is an anti-IL-6 receptor mAb, with immunosuppressive action that is approved for chronic autoimmune indications. Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Qyuns Therapeutics have a potential tocilizumab biosimilar (QX003S) in Phase 1 evaluation for rheumatoid arthritis (trial registry number ChiCTR1900021808). SARS-CoV-2 and COVID-19: In early March 2020, China's National Health Commission issued guidance that allows use of tocilizumab to treat patients with serious COVID-19-induced lung damage. Tocilizumab is predicted to mitigate against the uncontrolled immune response that is triggered by SARS-CoV-2 infection in some patients and which leads to potentially life-threatening damage to the lungs and other organs. Clinical trials are beginning to reveal outcomes (Oct 2020), but the level of benefit remains unclear and requires further investigations. Differences between the studies (timing of treatment, severity of disease at initiation of treatment etc.) make it difficult to compare results and form a solid conclusion. In early January 2021, data was reported from a small cohort of severely ill, mechanically ventilated COVID-19 patients in the REMAP-CAP trial (NCT02735707) who received tocilizumab. The information released (data not yet peer-reviewed) suggested that tocilizumab (compared to standard care) significantly reduced mortality and that patients treated with this mAb were able to leave intensive care 7-10 days earlier than those who didn't receive the drug. This effect appears to be in addition to the clinical benefit conferred by dexamathasone. As a result of this latest report, the UK Department of Health and Social Care was set to issue updated guidance (on 8th Jan; link to gov.uk press release) which will encourage NHS trusts across the UK to immediately begin using existing stocks of tocilizumab in their treatment of critically ill COVID-19 patients in ICUs.
单字母多肽序列
三字母多肽序列
翻译后修饰
化学修饰
临床描述	This is a randomized, double blind, multi-center study to evaluate the effects of tocilizumab compared to placebo on patient outcomes in participants with confirmed SARS-CoV-2 infection and evidence of systemic inflammation. The aim of this study is to test the effect of Tocilizumab on multi-organ dysfunction in a phase 3 randomized controlled trial among hospitalized patients with COVID-19 infection. Specifically, as compared to placebo, we will test whether tocilizumab is associated with a reduction in multi-organ dysfunction among hospitalized COVID-19 adult patients with elevated inflammatory measures. Multi-organ dysfunction will be measured as the incidence of the following composite endpoint (mechanical ventilation, renal replacement therapy, mechanical support, need for inotropes or vasopressors, liver dysfunction (increased bilirubin), and all-cause mortality). We will also assess multiple pre-specified secondary (exploratory) endpoints and safety endpoints. We hypothesize that, as compared to placebo, tocilizumab will reduce transfer to the ICU, need for mechanical ventilation, increase rates of hospital discharge in patients diagnosed with severe COVID-19 infection and evidence of exaggerated inflammatory response. The clinical study aims at assessing whether early administration of Tocilizumab compared to late administration of Tocilizumab can reduce the number of patients with COVID-19 pneumonia who require mechanical ventilation. The clinical study includes patients with recent-onset COVID-19 pneumonia who require hospital care, but not invasive or semi-invasive mechanical ventilation procedures. The overall objective of the study is to determine the therapeutic effect and tolerance of Tocizilumab in patients with moderate, severe pneumonia or critical pneumonia associated with Coronavirus disease 2019 (COVID-19). Tocilizumab (TCZ) is an anti-human IL-6 receptor monoclonal antibody that inhibits signal transduction by binding sIL-6R and mIL-6R. The study has a cohort multiple Randomized Controlled Trials (cmRCT) design. Randomization will occur prior to offering Tocilizumab administration to patients enrolled in the COVIMUNO-19 cohort. Tocilizumab will be administered to consenting adult patients hospitalized with CORVID-19 either diagnosed with moderate or severe pneumonia requiring no mechanical ventilation or critical pneumonia requiring mechanical ventilation. Patients who will chose not to receive Tocilizumab will receive standard of cares. Outcomes of Tocilizumab-treated patients will be compared with outcomes of standard of care treated patients as well as outcomes of patients treated with other immune modulators.
来源公司	Massachusetts General Hospital Azienda Unità Sanitaria Locale Reggio Emilia Assistance Publique - H?pitaux de Paris

参考文献

1. Maini RN, Taylor PC, Szechinski J, Pavelka K, Br?ll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J et al.. (2006) Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.. Arthritis Rheum, 54 (9): (2817-29). [PMID:16947782]
2. Paul-Pletzer K. (2006) Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders.. Drugs Today, 42 (9): (559-76). [PMID:17028666]
3. Matsuyama M, Suzuki T, Tsuboi H, Ito S, Mamura M, Goto D, Matsumoto I, Tsutsumi A, Sumida T. (2007) Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease.. Intern Med, 46 (11): (771-4). [PMID:17541233]
4. Nishimoto N, Kishimoto T. (2008) Humanized antihuman IL-6 receptor antibody, tocilizumab.. Handb Exp Pharmacol, 71 (181): (151-60). [PMID:18071945]
5. Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, Matsumoto Y, Ohsugi Y. (2005) Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.. Int Immunopharmacol, 5 (12): (1731-40). [PMID:16102523]
6. Yokota S, Miyamae T, Imagawa T, Katakura S, Kurosawa R, Mori M. (2005) Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis.. Clin Rev Allergy Immunol, 28 (3): (231-8). [PMID:16129907]
7. Ohsugi Y, Kishimoto T. (2008) The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis.. Expert Opin Biol Ther, 8 (5): (669-81). [PMID:18407769]
8. Unizony S, Kermani TA. (2018) IL-6 Blockade and its Therapeutic Success in Giant Cell Arteritis.. J Neuroophthalmol, 38 (4): (551-558). [PMID:30199509]
9. Gupta S, Wang W, Hayek SS, Chan L, Mathews KS, Melamed ML, Brenner SK, Leonberg-Yoo A, Schenck EJ, Radbel J et al.. (2021) Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19.. JAMA Intern Med, 181 (1): (41-51). [PMID:33080002]
10. Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S, Savoldi L, Bruzzi P, Boni F, Braglia L, Turrà C et al.. (2021) Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.. JAMA Intern Med, 181 (1): (24-31). [PMID:33080005]
11. Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P, CORIMUNO-19 Collaborative Group. (2021) Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.. JAMA Intern Med, 181 (1): (32-40). [PMID:33080017]
12. Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, Horick NK, Healy BC, Shah R, Bensaci AM et al.. (2020) Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.. N Engl J Med, 383 (24): (2333-2344). [PMID:33085857]
13. Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, Men D, Huang Q, Liu Y, Yang B et al.. (2020) Detectable Serum Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely Correlated With Drastically Elevated Interleukin 6 Level in Critically Ill Patients With Coronavirus Disease 2019.. Clin Infect Dis, 71 (8): (1937-1942). [PMID:32301997]
14. Wang W, Liu X, Wu S, Chen S, Li Y, Nong L, Lie P, Huang L, Cheng L, Lin Y et al.. (2020) Definition and Risks of Cytokine Release Syndrome in 11 Critically Ill COVID-19 Patients With Pneumonia: Analysis of Disease Characteristics.. J Infect Dis, 222 (9): (1444-1451). [PMID:32601708]

相关文档

质检报告COA

请输入批号:

SDS中文版 SDS英文版

质量技术规格说明书

产品问答

产品问答

登录提交问题

您提交该产品问题后,我们会在1-2个工作日内给您答复,您可以登录"我的账号",然后点击"我的产品问答"查看答案

上海阿拉丁生化科技股份有限公司

销售条款及条件 ? ? ? ? 隐私政策

? 2016 ALADDIN-E.COM . 版权所有,未经授权禁止拷贝本站资料,如有违反,将追究法律责任

沪公网安备 31012002004058号沪ICP备09093490号-2

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用。

危险品化学品经营许可证（带存储）

营业执照(三证合一)